AZD7624   Click here for help

GtoPdb Ligand ID: 11714

Synonyms: AZD-7624 | Example 259 [WO2009001132]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: AZD7624 is a p38α MAPK inhibitor [4]. It was designed as an inhalable agent to provide local anti-inflammatory action in inflammatory lung conditions [2-3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 11
Topological polar surface area 96.76
Molecular weight 491.23
XLogP 4.27
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CNCCOc1ccccc1C1(CC1)Nc1nccn(c1=O)c1cc(cc(c1C)F)C(=O)NC1CC1
Isomeric SMILES Cc1c(cc(cc1F)C(=O)NC1CC1)n1ccnc(c1=O)NC1(CC1)c1ccccc1OCCNC
InChI InChI=1S/C27H30FN5O3/c1-17-21(28)15-18(25(34)31-19-7-8-19)16-22(17)33-13-11-30-24(26(33)35)32-27(9-10-27)20-5-3-4-6-23(20)36-14-12-29-2/h3-6,11,13,15-16,19,29H,7-10,12,14H2,1-2H3,(H,30,32)(H,31,34)
InChI Key NNKPHNTWNILINE-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
AZD7624 (inhaled) has been assessed in healthy volunteers and phase 2a trials for chronic obstructive pulmonary disease (COPD) and corticosteroid resistant asthma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02753764 Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma Phase 2 Interventional National Jewish Health
NCT01754844 A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy Subjects Phase 1 Interventional AstraZeneca
NCT01937338 Study to Investigate the Effect of a Single Dose of AZD7624 on Inflammation Caused by an Endotoxin Challenge Phase 1 Interventional AstraZeneca 2
NCT02238483 A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy Phase 2 Interventional AstraZeneca 2